211315-53-6

Usage

Uses

Used in Organic Synthesis:
[(R)-2-(4-bromophenyl)propyl]carbamic acid tert-butyl ester is used as a building block in organic synthesis for the creation of a wide range of biologically active compounds. Its unique structure allows for the formation of diverse chemical entities with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [(R)-2-(4-bromophenyl)propyl]carbamic acid tert-butyl ester is used as a key intermediate in the synthesis of pharmaceutical drugs. Its incorporation into drug molecules can lead to the development of new therapeutic agents with improved efficacy and safety profiles.
It is crucial to handle and store this chemical according to proper safety procedures and guidelines, as it may pose hazards if mishandled.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 184773-89-5 1-bromo-4-(3-bromoprop-1-en-2-yl)benzene 
• 6888-79-5 4-bromo-α-methylstyrene 
• 99-90-1 para-bromoacetophenone 
• 119768-44-4 tert-butyl [(2R)-2-hydroxypropyl]carbamate 
• 863453-61-6 tert-butyl (5R)-5-methyl-2,2-dioxo-1,2λ⁶,3-oxathiazolidine-3-carboxylate 
• 589-87-7 1,4-bromoiodobenzene 
• 582-22-9 (R)-2-phenylpropylamine 

Downstream Products

• 1338544-01-6 (R)-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Highly Enantioselective Iridium-Catalyzed Hydrogenation of 2-Aryl Allyl Phthalimides

The iridium-catalyzed asymmetric hydrogenation of 2-aryl allyl phthalimides to afford enantioenriched β-aryl-β-methyl amines is presented. Recently developed Ir-MaxPHOX catalysts are used for this enantioselective transformation. The mild reaction conditions and the feasible removal of the phthalimido group makes this catalytic method easily scalable and of great interest to afford chiral amines. The importance of this new methodology is exemplified by the formal synthesis of (R)-Lorcaserin, OTS514, and enantiomerically enriched 3-methyl indolines.

Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK

T–lymphokine-activated killer cell–originated protein kinase (TOPK) is a serine-threonine mitogen-activated protein kinase that is highly expressed in many types of human cancer. Due to its important role in cancer progression, TOPK is becoming an attractive target in chemotherapeutic drug design. In this study, a series of 1-phenyl phenanthridin-6(5H)-one derivatives have been identified as a novel chemical class of TOPK inhibitors. Some of them displayed very potent anti-cancer activity with IC50s less than 100 nM, superior than reference compound OTS964. The most potent compound, 9g suppressed the growth of cancer cells by apoptosis and specifically inhibited the activities of TOPK. Oral administration of 9g effectively suppressed tumor growth with TGI >79.7% in colorectal cancer xenograft models, demonstrating superior efficacy compared to OTS964. Pharmacokinetic studies reveal its good oral bioavailability. Our findings therefore show that 9g is a specific inhibitor of TOPK both in vitro and in vivo that may be further developed as a potential therapeutic agent against colorectal cancer.

6 - Phenanthridone derivative and its preparation and use (by machine translation)

The invention belongs to the chemical field, and in particular relates to 6 - phenanthridone derivative and its preparation and use. The invention provides a 6 - phenanthridone derivatives, its structural formula as formula I shown. In addition, the inven

Ring opening of cyclic sulfamidates with bromophenyl metal reagents: Complementarity of sulfamidates and aziridines

Bromophenyl magnesium reagents generated via a Knochel type magnesium-halogen exchange of aryl iodides undergo regioselective ring opening of cyclic primary and secondary N-Boc sulfamidates in good to excellent yields. With secondary sulfamidates the reaction proceeds with clean inversion of the stereochemistry. This protocol complements the ring opening of aziridines with bromophenyl metal reagents and extends its scope to secondary substrates.

Sulphonamide derivatives

Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formulaR1—L—NHSO2R2??Iin whichR1 represents an unsubstituted or substituted aromatic or heteroaromatic group;R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl, (1-6C)chloroalkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, or a group, of formula R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group; andL represents a (2-4C)alkylene chain which is unsubstituted or substituted by one or two substituents selected independently from (1-6C)alkyl, aryl(1-6C)alkyl, (2-6C)alkenyl, aryl(2-6C)alkenyl and aryl, or by two substituents which, together with the carbon atom or carbon atoms to which they are attached form a (3-8C)carbocyclic ring;and pharmaceutically acceptable salts thereof.Also disclosed are compounds of formula I, processes for preparing them and pharmaceutical compositions containing them.